
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Acurx Pharmaceuticals LLC (ACXP)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ACXP (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $61.7
1 Year Target Price $61.7
1 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.77% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.72M USD | Price to earnings Ratio - | 1Y Target Price 61.7 |
Price to earnings Ratio - | 1Y Target Price 61.7 | ||
Volume (30-day avg) 3 | Beta -1.26 | 52 Weeks Range 3.80 - 44.90 | Updated Date 08/28/2025 |
52 Weeks Range 3.80 - 44.90 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.57 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.18 | Actual -1.89 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -98.59% | Return on Equity (TTM) -285.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1653726 | Price to Sales(TTM) - |
Enterprise Value 1653726 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.54 | Shares Outstanding 1584780 | Shares Floating 1311702 |
Shares Outstanding 1584780 | Shares Floating 1311702 | ||
Percent Insiders 8.12 | Percent Institutions 13.95 |
Upturn AI SWOT
Acurx Pharmaceuticals LLC

Company Overview
History and Background
Acurx Pharmaceuticals, LLC is a biopharmaceutical company focused on developing new antibiotics for difficult-to-treat infections. It focuses on developing and commercializing innovative technologies for the prevention and treatment of infectious diseases.
Core Business Areas
- Infectious Disease Therapeutics: Focused on developing antibiotics that address unmet needs in the treatment of bacterial infections, particularly C. difficile infections (CDI).
Leadership and Structure
Acurx is led by a management team with experience in drug development and commercialization. The specific details of the organizational structure and complete leadership team may be found on their investor relations page.
Top Products and Market Share
Key Offerings
- Ibezapolstat: A novel, orally administered, investigational agent being developed for the treatment of Clostridioides difficile infection (CDI). It is designed to selectively target C. difficile in the gut while sparing other beneficial bacteria. As this is still in development, there is no market share yet. Competitors in the CDI market include Merck (VZIO) with Dificid and Seres Therapeutics (MCRB) with VOWST.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the antibiotics market, is characterized by high R&D costs, stringent regulatory requirements, and increasing antibiotic resistance. The market for CDI therapeutics is substantial and growing, driven by aging populations and increased healthcare-associated infections.
Positioning
Acurx is positioned as an innovator in the field of microbiome-sparing antibiotics, with Ibezapolstat representing a potentially differentiated approach to CDI treatment.
Total Addressable Market (TAM)
The global Clostridium difficile infection treatment market size was valued at $1.8 billion in 2023 and is expected to reach $2.8 billion by 2032, according to Allied Market Research. Acurx is positioned to capture a portion of this TAM with successful Ibezapolstat commercialization.
Upturn SWOT Analysis
Strengths
- Novel microbiome-sparing approach
- Potential for improved CDI treatment outcomes
- Strong intellectual property position
Weaknesses
- Reliance on a single lead product (Ibezapolstat)
- Clinical trial and regulatory risks
- Limited commercial infrastructure
Opportunities
- Expansion into other infectious disease indications
- Partnerships with larger pharmaceutical companies
- Growing awareness of microbiome-sparing antibiotics
Threats
- Competition from established CDI treatments
- Changes in regulatory landscape
- Failure to achieve clinical trial success
Competitors and Market Share
Key Competitors
- MRK
- MCRB
Competitive Landscape
Acurx's advantage lies in its novel microbiome-sparing approach, but it faces competition from established therapies like Dificid (Merck) and VOWST (Seres). Success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the progression of Ibezapolstat through clinical trials and the associated market capitalization changes.
Future Projections: Future growth depends heavily on the successful completion of clinical trials, regulatory approval, and subsequent commercialization of Ibezapolstat. Analyst estimates aren't widely available due to the early stage nature of the company.
Recent Initiatives: Recent initiatives focus on advancing Ibezapolstat through Phase 3 clinical trials and exploring potential partnerships.
Summary
Acurx Pharmaceuticals is a development-stage company with a focus on microbiome-sparing antibiotics, particularly Ibezapolstat for CDI. Its success is contingent on clinical trial outcomes and regulatory approval, making it a high-risk, high-reward investment. The company's novel approach offers potential differentiation, but it faces competition from established players. Continued clinical progress and strategic partnerships are critical for its future growth. Investors should monitor clinical trial results and cash runway closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Industry reports
- Company website
- Allied Market Research reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acurx Pharmaceuticals LLC
Exchange NASDAQ | Headquaters Staten Island, NY, United States | ||
IPO Launch date 2021-06-25 | Co-Founder, President, CEO, Corporate Secretary & Director Mr. David P. Luci CPA, Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.acurxpharma.com |
Full time employees 4 | Website https://www.acurxpharma.com |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.